RORC SNPs | Chronic HCVb (n = 54) | Resolved HCVb (n = 67) | P-value | OR (95% CI) |
---|
rs9826 |
CC | 5 (0.09) | 1 (0.01) | 0.092 | |
TT | 26 (0.48) | 41 (0.61) |
CT | 23 (0.43) | 25 (0.37) |
C allele | 33 (0.31) | 27 (0.20) | 0.062 | 1.74 (0.97–3.19) |
T allele | 75 (0.69) | 107 (0.80) | 0.57 (0.31–1.03) |
rs1521177 |
GG | 6 (0.11) | 1 (0.01) |
0.040
| |
TT | 26 (0.48) | 43 (0.64) |
GT | 22 (0.41) | 23 (0.34) |
G allele | 34 (0.31) | 25 (0.19) |
0.021
| 2.00 (1.11–3.55) |
T allele | 74 (0.69) | 109 (0.81) | 0.50 (0.28–0.90) |
- aParticipants in the, IFNL3 favorable sub-cohort were screened for, IFNL3 genotypes (rs12979860CC/rs8099917TT/rs12980275AA)
- bNumber of cases (frequency)
- SNP genotyping was conducted using the iPLEX MassARRAY system (Sequenom Inc., USA), and allele and genotype frequency distributions were calculated. Chi-square (χ2) and Fisher’s exact tests were used to evaluate differences in, SNP frequencies between, HCV carriers and spontaneous resolvers. P-values, odds ratios, (ORs) and 95% confidence intervals, (95% CIs) were determined for association analysis. P-values (two-tailed) < 0.05were considered significant (bold)